News

The question is, how much attention should be paid to historical recruitment figures if the team only reviews the data from one (or two) similar studies?

Updated employee announcements, business news, awards, and recognition in the industry today.

In this interview, Jim Streeter, Global Vice President of Life Sciences Product Strategy at Oracle, will elaborate further on Oracle’s strategy with mHealth in clinical trials.

The British government has at last set out its ambitions for cooperation on medicines post-Brexit.

The potential for innovative gene therapies to treat and even cure a range of serious diseases is prompting FDA to ramp up support for developing and testing new products efficiently and effectively.

Given the rapid changes in the communication landscape brought about by participative Internet use and social media, it is important to develop a better understanding of these technologies and their impact on health communication.

Patients stand to lose the most when sponsors hold too tightly to drugs doomed to fail. This wastes precious time that patients don’t have and squanders valuable resources.

// You can adjust the form size here: var DrupalLeadsFormWidth = 870; var DrupalLeadsFormHeight = 2500;

Exploring that pivotal question for clinical investigators, sponsors, and global CROs.

FDA is testing various strategies to streamline research and regulatory oversight by looking to novel clinical trial designs to advance new treatments.

Although Biogen's Alzheimer's drug BAN2401 addresses buildup of amyloid plaques, investors and scientists look to reevaluate the plaque theory and search for a glimmer of hope in breakthrough treatments.

The Business Research Company publishes a report that the global market for clinical trial services to biopharmaceutical and medical device companies is forecast to grow at 12% year-on-year to 2021.